Retraction: MicroRNA-410 Suppresses Migration and Invasion by Targeting MDM2 in Gastric Cancer (PLoS ONE (2014) 9:8 (e104510) DOI: 10.1371/journal.pone.0104510);MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Shen, Jianjun ^a   Niu, Weina ^b   Zhou, Ming ^a   Zhang, Hongbo ^a   Ma, Jun ^a   Wang, Ling ^a   Zhang, Hongyan ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b Anhui Cancer Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 410; PROTEIN MDM2; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MDM2 PROTEIN, HUMAN; MIRN410 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GASTRIC CANCER CELL LINE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MDM2 GENE; MIGRATION INHIBITION; PROTEIN EXPRESSION; PROTEIN TARGETING; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR INVASION; CELL MOTION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REPORTER GENE; STOMACH TUMOR; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEK293 CELLS; HUMANS; LUCIFERASES; LYMPHATIC METASTASIS; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MDM2; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84921464923     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0269898     Document Type: Erratum

References (35)

1. Thiel A, Ristimaki A (2012) Gastric cancer: basic aspects. Helicobacter 17 Suppl 1: 26-29.
2. Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20.
3. Song MY, Pan KF, Su HJ, Zhang L, Ma JL, et al. (2012) Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 7: e33608.
4. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, et al. (2011) MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One 6: e16617.
5. Kang W, Tong JH, Chan AW, Lung RW, Chau SL, et al. (2012) Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 7: e33919.
6. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, et al. (2013) The tumorsuppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One 8: e60155.
7. Yu X, Li Z, Shen J, Wu WK, Liang J, et al. (2013) MicroRNA-10b Promotes Nucleus Pulposus Cell Proliferation through RhoC-Akt Pathway by Targeting HOXD10 in Intervetebral Disc Degeneration. PLoS One 8: e83080.
8. Hummel R, Hussey DJ, Haier J (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46: 298-311.
9. Li Z, Lei H, Luo M, Wang Y, Dong L, et al. (2014) DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer.
10. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, et al. (2010) MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer.
11. Dong Z, Zhong Z, Yang L, Wang S, Gong Z (2014) MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 343: 249-257.
12. Kim J, Choi NE, Oh SJ, Park SJ, Kim HK (2011) Combined expression of miR-122a, miR-1, and miR-200b can differentiate degraded RNA samples from liver, pancreas, and stomach. Pathol Int 61: 67-72.
13. Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, et al. (2011) Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 117: 6227-6236.
14. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, et al. (2011) miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 protooncogene in human invasive breast cancer. Cancer Res 71: 3552-3562.
15. Kunte DP, Delacruz M, Wali RK, Menon A, Du H, et al. (2012) Dysregulation of MicroRNAs in Colonic Field Carcinogenesis: Implications for Screening. PLoS One 7: e45591.
16. Gattolliat CH, Thomas L, Ciafre SA, Meurice G, Le Teuff G, et al. (2011) Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer 105: 1352-1361.
17. Chen L, Zhang J, Feng Y, Li R, Sun X, et al. (2012) MiR-410 regulates MET to influence the proliferation and invasion of glioma. Int J Biochem Cell Biol 44: 1711-1717.
18. Chien WW, Domenech C, Catallo R, Kaddar T, Magaud JP, et al. (2011) Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway. Oncogene 30: 1880-1891.
19. Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, et al. (2012) Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 7: e48086.
20. Zhao G, Cai C, Yang T, Qiu X, Liao B, et al. (2013) MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 8: e53906.
21. Kobayashi E, Hornicek FJ, Duan Z (2012) MicroRNA Involvement in Osteosarcoma. Sarcoma 2012: 359739.
22. Truini A, Coco S, Alama A, Genova C, Sini C, et al. (2014) Role of microRNAs in malignant mesothelioma. Cell Mol Life Sci.
23. Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, et al. (2014) MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett.
24. Craig VJ, Cogliatti SB, Rehrauer H, Wundisch T, Muller A (2011) Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helico-bacter- associated gastric lymphomagenesis. Cancer Res 71: 3616-3624.
25. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, et al. (2010) Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18: 367-381.
26. Zhao Y, Yu H, Hu W (2014) The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai) 46: 180-189.
27. Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, et al. (2014) Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem 21: 553-574.
28. Shangary S, Wang S (2008) Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14: 5318-5324.
29. Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R (2013) The MDM2-p53 pathway revisited. J Biomed Res 27: 254-271.
30. Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83-96.
31. Li Q, Lozano G (2013) Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 19: 34-41.
32. Peng Q, Lao X, Chen Z, Lai H, Deng Y, et al. (2013) TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One 8: e82773.
33. Park HS, Park JM, Park S, Cho J, Kim SI, et al. (2013) Subcellular localization of Mdm2 expression and prognosis of breast cancer. Int J Clin Oncol.
34. Gunther T, Schneider-Stock R, Hackel C, Kasper HU, Pross M, et al. (2000) Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol 13: 621-626. (Pubitemid 30436797)
35. Ye Y, Li X, Yang J, Miao S, Wang S, et al. (2013) MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci 104: 590-598.